Foretinib is an experimental drug candidate for the treatment of cancer. It was discovered by Exelixis and is under development by GlaxoSmithKline. About 10 Phase II clinical trials have been run. As of October 2015[update] it appears development has been discontinued.
Foretinib is an inhibitor of the kinase enzymes c-Met and vascular endothelial growth factor receptor 2 (VEGFR-2).
See also
- c-Met inhibitors
- Cabozantinib, a similar molecule and kinase inhibitor with FDA approval
- VEGFR inhibitor
- tyrosine-kinase inhibitor
References
Hedgethorne, K.; Huang, P.H. (2010). "Foretinib. c-Met and VEGFR-2 inhibitor, Oncolytic". Drugs of the Future. 35 (11): 893–901. doi:10.1358/dof.2010.35.11.1529012. /wiki/Doi_(identifier) ↩
"XL880 (GSK1363089)". Exelixis, Inc. http://www.exelixis.com/pipeline/xl880 ↩
"Foretinib". clinicaltrials.gov. https://clinicaltrials.gov/ct2/results?term=Foretinib+ ↩
"Foretinib - AdisInsight". adisinsight.springer.com. Retrieved 16 April 2018. http://adisinsight.springer.com/drugs/800022245 ↩
Qian, F; Engst, S; Yamaguchi, K; Yu, P; Won, KA; Mock, L; Lou, T; Tan, J; et al. (2009). "Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases". Cancer Research. 69 (20): 8009–16. doi:10.1158/0008-5472.CAN-08-4889. PMID 19808973. /wiki/Doi_(identifier) ↩